Compare BAK & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAK | NNNN |
|---|---|---|
| Founded | 1972 | 2021 |
| Country | Brazil | Germany |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2025 |
| Metric | BAK | NNNN |
|---|---|---|
| Price | $2.96 | $38.50 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.40 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 26.4K |
| Earning Date | 11-11-2025 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | ★ $13,841,708,237.00 | $8,185,146.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.01 | N/A |
| P/E Ratio | ★ N/A | $721.40 |
| Revenue Growth | N/A | ★ 21.95 |
| 52 Week Low | $2.32 | $5.18 |
| 52 Week High | $5.26 | $55.65 |
| Indicator | BAK | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 53.63 | 70.23 |
| Support Level | $2.82 | $21.13 |
| Resistance Level | $3.11 | $29.38 |
| Average True Range (ATR) | 0.15 | 4.90 |
| MACD | -0.00 | 2.09 |
| Stochastic Oscillator | 25.58 | 80.87 |
Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.